Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 03-Apr-24 4:13 PM View:  | Swartz Robin Chief Operating Officer | Voyager Therapeutics, Inc. (VYGR) | 02-Apr-24 | Private Sale | 1,357 | $9.88 | $13,407.20 | (1%) 118.36K to 117.0K | |
| 03-Apr-24 4:10 PM View: | Sandrock Alfred President and CEO Director | Voyager Therapeutics, Inc. (VYGR) | 02-Apr-24 | Private Sale | 12,115 | $9.86 | $119,454.00 | (4%) 334.95K to 322.84K | |
| 03-Apr-24 4:17 PM View: | Ferguson Toby Chief Medical Officer | Voyager Therapeutics, Inc. (VYGR) | 01-Apr-24 | Grant | 105,000 | -- | -- | 100% 0 to 105.0K | |
| 22-Feb-24 4:30 PM View: | Carter Todd Alfred Chief Scientific Officer | Voyager Therapeutics, Inc. (VYGR) | 21-Feb-24 | Sale | 3,365 | $7.47 | $25,136.50 | (4%) 90.99K to 87.63K | |
| 22-Feb-24 4:32 PM View: | Pfreundschuh Peter P. Chief Financial Officer | Voyager Therapeutics, Inc. (VYGR) | 21-Feb-24 | Private Sale | 3,764 | $7.46 | $28,079.40 | (2%) 179.43K to 175.67K | |
| 22-Feb-24 4:36 PM View: | Swartz Robin Chief Operating Officer | Voyager Therapeutics, Inc. (VYGR) | 21-Feb-24 | Private Sale | 3,966 | $7.45 | $29,546.70 | (3%) 122.33K to 118.36K | |
| 22-Feb-24 4:34 PM View: | Sandrock Alfred President and CEO Director | Voyager Therapeutics, Inc. (VYGR) | 21-Feb-24 | Private Sale | 13,033 | $7.46 | $97,226.20 | (4%) 347.99K to 334.95K | |
| 22-Feb-24 4:30 PM View: | Carter Todd Alfred Chief Scientific Officer | Voyager Therapeutics, Inc. (VYGR) | 20-Feb-24 | Private Sale | 602 | $7.68 | $4,623.36 | (< 1%) 91.59K to 90.99K | |
| 16-Feb-24 4:58 PM View: | Pfreundschuh Peter P. Chief Financial Officer | Voyager Therapeutics, Inc. (VYGR) | 09-Feb-24 | Grant | 30,000 | -- | -- | 20% 149.43K to 179.43K | |
| 16-Feb-24 5:03 PM View: | Swartz Robin Chief Operating Officer | Voyager Therapeutics, Inc. (VYGR) | 09-Feb-24 | Grant | 50,000 | -- | -- | 69% 72.33K to 122.33K | |
| 16-Feb-24 5:04 PM View: | Carter Todd Alfred Chief Scientific Officer | Voyager Therapeutics, Inc. (VYGR) | 09-Feb-24 | Grant | 38,500 | -- | -- | 73% 53.09K to 91.59K | |
| 16-Feb-24 4:59 PM View: | Sandrock Alfred President and CEO Director | Voyager Therapeutics, Inc. (VYGR) | 09-Feb-24 | Grant | 130,000 | -- | -- | 60% 217.99K to 347.99K | |
| 16-Feb-24 5:06 PM View: | Fahey Sandell Jacquelyn Chief Legal Officer | Voyager Therapeutics, Inc. (VYGR) | 09-Feb-24 | Grant | 31,000 | -- | -- | 51% 61.0K to 92.0K | |
| 19-Jan-24 4:34 PM View: | Swartz Robin Chief Operating Officer | Voyager Therapeutics, Inc. (VYGR) | 17-Jan-24 | Private Sale | 2,543 | $7.15 | $18,182.50 | (3%) 74.87K to 72.33K | |
| 19-Jan-24 4:32 PM View: | Carter Todd Alfred Chief Scientific Officer | Voyager Therapeutics, Inc. (VYGR) | 17-Jan-24 | Private Sale | 1,266 | $7.18 | $9,089.88 | (2%) 54.36K to 53.09K | |
| 05-Oct-23 4:41 PM View: | Pfreundschuh Peter P. Chief Financial Officer | Voyager Therapeutics, Inc. (VYGR) | 03-Oct-23 | Private Sale | 13,567 | $6.99 | $94,833.30 | (8%) 163.0K to 149.43K | |
| 02-Oct-23 4:24 PM View: | Fahey Sandell Jacquelyn Chief Legal Officer | Voyager Therapeutics, Inc. (VYGR) | 01-Oct-23 | Grant | 61,000 | -- | -- | 100% 0 to 61.0K | |
| 18-Sep-23 4:44 PM View: | Carter Todd Alfred Chief Scientific Officer | Voyager Therapeutics, Inc. (VYGR) | 15-Sep-23 | Option Exercise | 5,000 | $2.85 | $14,250.00 | 4% 124.72K to 129.72K | (< 1%) |
| 18-Sep-23 4:44 PM View: | Carter Todd Alfred Chief Scientific Officer | Voyager Therapeutics, Inc. (VYGR) | 15-Sep-23 | Planned Private Option Sale | 5,000 | $8.16 | $40,800.00 | (4%) 129.72K to 124.72K | |
| 18-Sep-23 4:44 PM View: | Carter Todd Alfred Chief Scientific Officer | Voyager Therapeutics, Inc. (VYGR) | 15-Sep-23 | Sale (Planned) | 5,500 | $8.16 | $44,880.00 | (4%) 124.72K to 119.22K | |
| 10-Jul-23 4:42 PM View: | Carter Todd Alfred Chief Scientific Officer | Voyager Therapeutics, Inc. (VYGR) | 06-Jul-23 | Private Sale (Planned) | 5,500 | $10.80 | $59,400.00 | (8%) 65.36K to 59.86K | |
| 05-Jul-23 4:32 PM View: | Carter Todd Alfred Chief Scientific Officer | Voyager Therapeutics, Inc. (VYGR) | 30-Jun-23 | Option Exercise | 5,000 | $2.85 | $14,250.00 | 4% 135.72K to 140.72K | (< 1%) |
| 05-Jul-23 4:32 PM View: | Carter Todd Alfred Chief Scientific Officer | Voyager Therapeutics, Inc. (VYGR) | 30-Jun-23 | Planned Private Option Sale | 5,000 | $11.41 | $57,050.00 | (4%) 140.72K to 135.72K | |
| 05-Apr-23 5:04 PM View: | Sandrock Alfred President and CEO Director | Voyager Therapeutics, Inc. (VYGR) | 03-Apr-23 | Private Sale | 7,437 | $7.83 | $58,231.70 | (3%) 222.06K to 214.62K | |
| 05-Apr-23 5:02 PM View: | Swartz Robin Chief Operating Officer | Voyager Therapeutics, Inc. (VYGR) | 03-Apr-23 | Private Sale | 1,259 | $7.83 | $9,857.97 | (2%) 72.88K to 71.62K | |
| 22-Mar-23 4:48 PM View: | Swartz Robin Chief Operating Officer | Voyager Therapeutics, Inc. (VYGR) | 20-Mar-23 | Private Sale (Planned) | 3,654 | $7.76 | $28,355.00 | (5%) 76.53K to 72.88K | |
| 22-Mar-23 4:47 PM View: | Hesslein Robert W. Senior VP & General Counsel | Voyager Therapeutics, Inc. (VYGR) | 20-Mar-23 | Private Sale (Planned) | 4,410 | $7.76 | $34,221.60 | (4%) 106.61K to 102.2K | |
| 22-Mar-23 4:49 PM View: | Carter Todd Alfred Chief Scientific Officer | Voyager Therapeutics, Inc. (VYGR) | 20-Mar-23 | Private Sale (Planned) | 2,193 | $7.76 | $17,017.70 | (3%) 67.55K to 65.36K | |
| 17-Mar-23 4:37 PM View: | Swartz Robin Chief Operating Officer | Voyager Therapeutics, Inc. (VYGR) | 15-Mar-23 | Private Sale | 15,373 | $8.20 | $126,059.00 | (17%) 91.9K to 76.53K | |
| 24-Feb-23 6:15 AM View: | Neurocrine Biosciences Inc 10% Owner | Voyager Therapeutics, Inc. (VYGR) | 23-Feb-23 | Purchase | 4,395,590 | $8.88 | $39,032,800.00 | 105% 4.18M to 8.58M | |
| 22-Feb-23 8:57 PM View: | Carter Todd Alfred Chief Scientific Officer | Voyager Therapeutics, Inc. (VYGR) | 17-Feb-23 | Grant | 34,000 | -- | -- | 99% 34.29K to 68.29K | |
| 22-Feb-23 8:58 PM View: | Hesslein Robert W. Senior VP & General Counsel | Voyager Therapeutics, Inc. (VYGR) | 17-Feb-23 | Private Sale (Planned) | 3,297 | $7.45 | $24,562.60 | (3%) 109.91K to 106.61K | |
| 22-Feb-23 8:55 PM View: | Pfreundschuh Peter P. Chief Financial Officer | Voyager Therapeutics, Inc. (VYGR) | 17-Feb-23 | Grant | 38,000 | -- | -- | 30% 125.0K to 163.0K | |
| 22-Feb-23 8:52 PM View: | Swartz Robin Chief Operating Officer | Voyager Therapeutics, Inc. (VYGR) | 17-Feb-23 | Grant | 40,000 | -- | -- | 77% 51.9K to 91.9K | |
| 22-Feb-23 8:57 PM View: | Carter Todd Alfred Chief Scientific Officer | Voyager Therapeutics, Inc. (VYGR) | 17-Feb-23 | Sale (Planned) | 738 | $7.45 | $5,498.10 | (1%) 68.29K to 67.55K | |
| 22-Feb-23 8:51 PM View: | Sandrock Alfred President and CEO Director | Voyager Therapeutics, Inc. (VYGR) | 17-Feb-23 | Grant | 120,000 | -- | -- | 118% 102.06K to 222.06K | |
| 15-Feb-23 4:53 PM View: | Carter Todd Alfred Chief Scientific Officer | Voyager Therapeutics, Inc. (VYGR) | 13-Feb-23 | Private Sale (Planned) | 797 | $7.67 | $6,112.99 | (2%) 35.09K to 34.29K | |
| 15-Feb-23 4:52 PM View: | Hesslein Robert W. Senior VP & General Counsel | Voyager Therapeutics, Inc. (VYGR) | 13-Feb-23 | Private Sale (Planned) | 2,868 | $7.67 | $21,997.60 | (3%) 112.78K to 109.91K | |
| 06-Feb-23 4:30 PM View: | Third Rock Ventures Iii, L.P. 10% Owner | Voyager Therapeutics, Inc. (VYGR) | 02-Feb-23 | Disposition (other) | 1,500,000 | -- | -- | (31%) 4.77M to 3.27M | |
| 01-Feb-23 7:26 PM View: | Third Rock Ventures Iii, L.P. 10% Owner | Voyager Therapeutics, Inc. (VYGR) | 01-Feb-23 | Sale | 128,642 | $9.32 | $1,198,940.00 | (3%) 4.85M to 4.72M | |
| 01-Feb-23 7:26 PM View: | Third Rock Ventures Iii, L.P. 10% Owner | Voyager Therapeutics, Inc. (VYGR) | 31-Jan-23 | Sale | 185,000 | $9.25 | $1,711,250.00 | (4%) 5.04M to 4.85M | |
| 01-Feb-23 7:26 PM View: | Third Rock Ventures Iii, L.P. 10% Owner | Voyager Therapeutics, Inc. (VYGR) | 30-Jan-23 | Private Sale | 75,000 | $9.03 | $677,250.00 | (1%) 5.11M to 5.04M | |
| 31-Jan-23 4:30 PM View: | Third Rock Ventures Iii, L.P. 10% Owner | Voyager Therapeutics, Inc. (VYGR) | 27-Jan-23 | Private Sale | 50,000 | $9.02 | $451,000.00 | (< 1%) 5.16M to 5.11M | |
| 26-Jan-23 5:23 PM View: | Third Rock Ventures Iii, L.P. 10% Owner | Voyager Therapeutics, Inc. (VYGR) | 25-Jan-23 | Sale | 50,000 | $9.22 | $461,000.00 | (< 1%) 5.21M to 5.16M | |
| 26-Jan-23 5:23 PM View: | Third Rock Ventures Iii, L.P. 10% Owner | Voyager Therapeutics, Inc. (VYGR) | 24-Jan-23 | Private Sale | 100,000 | $9.27 | $927,000.00 | (2%) 5.31M to 5.21M | |
| 24-Jan-23 6:20 PM View: | Third Rock Ventures Iii, L.P. 10% Owner | Voyager Therapeutics, Inc. (VYGR) | 23-Jan-23 | Sale | 55,000 | $9.06 | $498,300.00 | (1%) 5.37M to 5.31M | |
| 24-Jan-23 6:20 PM View: | Third Rock Ventures Iii, L.P. 10% Owner | Voyager Therapeutics, Inc. (VYGR) | 20-Jan-23 | Private Sale | 100,000 | $9.15 | $915,000.00 | (2%) 5.47M to 5.37M | |
| 19-Jan-23 4:57 PM View: | Hesslein Robert W. Senior VP & General Counsel | Voyager Therapeutics, Inc. (VYGR) | 17-Jan-23 | Private Sale (Planned) | 2,188 | $9.85 | $21,549.00 | (2%) 114.96K to 112.78K | |
| 19-Jan-23 4:55 PM View: | Carter Todd Alfred Chief Scientific Officer | Voyager Therapeutics, Inc. (VYGR) | 17-Jan-23 | Private Sale (Planned) | 1,106 | $9.85 | $10,892.40 | (3%) 36.19K to 35.09K | |
| 19-Jan-23 4:53 PM View: | Swartz Robin Chief Operating Officer | Voyager Therapeutics, Inc. (VYGR) | 17-Jan-23 | Private Sale (Planned) | 2,188 | $9.85 | $21,549.00 | (4%) 54.09K to 51.9K |
